This trial is active, not recruiting.

Condition dyspepsia
Treatment itopride hydrochloride
Phase phase 3
Sponsor Axcan Pharma
Start date November 2004
End date August 2006
Trial size 300 participants
Trial identifier NCT00112203, ITOFD04-04


Itopride is a compound already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms of functional dyspepsia. Patients suffering from this condition have difficulties digesting food. Patients feel full after eating; they have bloating and have stomach pain. The goal of this study is to see if itopride helps to relieve the symptoms of functional dyspepsia on a long-term basis.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Long-term safety
time frame:

Secondary Outcomes

Long-term relief of symptoms
time frame:

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Patients must have completed the 8 week double-blind study ITOFD04-03 - Female patients must not be pregnant (must have a negative serum pregnancy test) Exclusion Criteria: - Patients with any newly occurring medical condition which was an exclusion criterion at ITOFD04-03 study entry

Additional Information

Official title A Multicentre, Open-Label Extension Phase to Study the Long-Term Safety and Efficacy of Itopride HCl in Patients Suffering From Functional Dyspepsia
Principal investigator Jan Tack, MD
Description All patients who have completed study ITOFD04-03 will be offered to continue to be treated with itopride for a period of up to one year in duration. A target of 300 patients will be followed up for 6 months. Of these, a target of 100 patients will be kept on treatment for an additional 6 months. Patients will need to come to the clinic for evaluations every 8 weeks during the trial. Evaluations done at these visits will include: lab tests, evaluation of the heartburn condition, and a questionnaire needed to be completed by the patient to see if the drug is helpful in relieving their symptoms.
Trial information was received from ClinicalTrials.gov and was last updated in January 2007.
Information provided to ClinicalTrials.gov by Axcan Pharma.